Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Metformin Hydrochloride in Idiopathic Pulmonary Fibrosis: NCT07520110 Clinical Landscape Report 2026
9 min read
Metformin Hydrochloride in Idiopathic Pulmonary Fibrosis: NCT07520110 Clinical Landscape Report 2026
16 September 2026
NCT07520110 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
PF-08046033 (GPS) in Esophageal Carcinoma: NCT07519655 Clinical Landscape Report 2026
9 min read
PF-08046033 (GPS) in Esophageal Carcinoma: NCT07519655 Clinical Landscape Report 2026
16 September 2026
NCT07519655 clinical landscape for Esophageal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fludarabine Phosphate in Idiopathic Inflammatory Myopathies: NCT07526493 Clinical Landscape Report 2026
9 min read
Fludarabine Phosphate in Idiopathic Inflammatory Myopathies: NCT07526493 Clinical Landscape Report 2026
16 September 2026
NCT07526493 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
Read →
Pegfilgrastim (Amgen) in Triple Negative Breast Cancer: NCT07525869 Clinical Landscape Report 2026
9 min read
Pegfilgrastim (Amgen) in Triple Negative Breast Cancer: NCT07525869 Clinical Landscape Report 2026
16 September 2026
NCT07525869 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Gemcitabine Hydrochloride in Metastatic Triple-Negative Breast Carcinoma: NCT07528768 Clinical Landscape Report 2026
9 min read
Gemcitabine Hydrochloride in Metastatic Triple-Negative Breast Carcinoma: NCT07528768 Clinical Landscape Report 2026
16 September 2026
NCT07528768 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
Read →
Pomalidomide in Refractory Central Nervous System Lymphoma: NCT07523737 Clinical Landscape Report 2026
9 min read
Pomalidomide in Refractory Central Nervous System Lymphoma: NCT07523737 Clinical Landscape Report 2026
16 September 2026
NCT07523737 clinical landscape for Refractory Central Nervous System Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
Read →
RGT-490 in Locally Advanced Malignant Solid Neoplasm: NCT07524322 Clinical Landscape Report 2026
9 min read
RGT-490 in Locally Advanced Malignant Solid Neoplasm: NCT07524322 Clinical Landscape Report 2026
16 September 2026
NCT07524322 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
Fludarabine Phosphate in Lupus Nephritis: NCT07523542 Clinical Landscape Report 2026
9 min read
Fludarabine Phosphate in Lupus Nephritis: NCT07523542 Clinical Landscape Report 2026
16 September 2026
NCT07523542 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
HN-2302 in Scleroderma, Diffuse: NCT07523282 Clinical Landscape Report 2026
9 min read
HN-2302 in Scleroderma, Diffuse: NCT07523282 Clinical Landscape Report 2026
16 September 2026
NCT07523282 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
RC-010 in Idiopathic Pulmonary Fibrosis: NCT07528703 Clinical Landscape Report 2026
9 min read
RC-010 in Idiopathic Pulmonary Fibrosis: NCT07528703 Clinical Landscape Report 2026
16 September 2026
NCT07528703 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Glofitamab in Diffuse Large B-Cell Lymphoma: NCT07528352 Clinical Landscape Report 2026
9 min read
Glofitamab in Diffuse Large B-Cell Lymphoma: NCT07528352 Clinical Landscape Report 2026
16 September 2026
NCT07528352 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Inavolisib in Advanced Endometrial Carcinoma: NCT07522697 Clinical Landscape Report 2026
9 min read
Inavolisib in Advanced Endometrial Carcinoma: NCT07522697 Clinical Landscape Report 2026
16 September 2026
NCT07522697 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →